US20170021020A1 - Monoclonal antibody and vaccine targeting filamentous bacteriophage - Google Patents
Monoclonal antibody and vaccine targeting filamentous bacteriophage Download PDFInfo
- Publication number
- US20170021020A1 US20170021020A1 US15/219,073 US201615219073A US2017021020A1 US 20170021020 A1 US20170021020 A1 US 20170021020A1 US 201615219073 A US201615219073 A US 201615219073A US 2017021020 A1 US2017021020 A1 US 2017021020A1
- Authority
- US
- United States
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- consisting essentially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 19
- 241000724791 Filamentous phage Species 0.000 title description 4
- 230000008685 targeting Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 239000012634 fragment Substances 0.000 claims abstract description 51
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 241001515965 unidentified phage Species 0.000 claims abstract description 51
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 49
- 108091007433 antigens Proteins 0.000 claims abstract description 49
- 101710107870 Phosphopantothenate-cysteine ligase Proteins 0.000 claims abstract description 37
- 241000282414 Homo sapiens Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000032770 biofilm formation Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 112
- 102000040430 polynucleotide Human genes 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 22
- 239000002157 polynucleotide Substances 0.000 claims description 22
- 239000003242 anti bacterial agent Substances 0.000 claims description 20
- 229940088710 antibiotic agent Drugs 0.000 claims description 16
- 230000003115 biocidal effect Effects 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000019206 urinary tract infection Diseases 0.000 claims description 4
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000008520 organization Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229960000707 tobramycin Drugs 0.000 description 7
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 7
- 101710132601 Capsid protein Proteins 0.000 description 6
- 101710094648 Coat protein Proteins 0.000 description 6
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 101710141454 Nucleoprotein Proteins 0.000 description 6
- 101710083689 Probable capsid protein Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000004973 liquid crystal related substance Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- -1 ceftazidime) Chemical class 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- Pseudomonas aeruginosa is an opportunistic pathogen in multiple clinical settings, including devastating pulmonary infections in individuals with the genetic disorder cystic fibrosis (CF).
- CF cystic fibrosis
- the virulence of P. aeruginosa is predicated on its ability to form biofilms, which are organized communities of bacteria encased in a polymer-rich matrix. Bacterial biofilms are ubiquitous in nature, and they endow bacteria with the ability to resist antibiotics and evade host immune defense mechanisms. See Costerton et al., Science 284:1318 (1999); Stewart et al., Int. J. Med. Microbiol. 292:107 (2002).
- Many embodiments described herein relate to a method for reducing or preventing P. aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage.
- the first composition comprises an antigen-binding polypeptide.
- the antigen-binding polypeptide binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
- the antigen-binding polypeptide is IgG or IgM.
- the first composition further comprises an antibiotic
- the method further comprises administering a second composition comprising an antibiotic to the human subject.
- the human subject is infected with a P. aeruginosa strain resistant to one or more antibiotics.
- the first composition comprises a vaccine against Pf-family bacteriophage.
- the vaccine comprises an immunogenic fragment of Pf-family bacteriophage.
- the CoaB protein or fragment thereof comprises the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO: 1).
- the human subject is suffering from cystic fibrosis, burns, chronic would, chronic rhinosinusitis, ventilator-associated pneumonia, catheter-associated urinary tract infections, septic shock, and/or gastrointestinal infections.
- an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
- the antigen-binding polypeptide specifically binds to an antigenic fragment of the CoaB protein comprising the amino acid sequence of
- the antigen-binding polypeptide is a monoclonal antibody, a chimeric antibody, a humanized antibody, a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, or an scFv molecule. In one embodiment, the antigen-binding polypeptide is IgG or IgM.
- Another embodiment described herein relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) the antigen-binding polypeptide described herein or a fusion molecule comprising the antigen-binding polypeptide, and (b) a pharmaceutically acceptable carrier.
- Another embodiment described herein relates to a polynucleotide encoding the antigen-binding polypeptide described herein.
- Another embodiment described herein relates to an expression cassette comprising a promoter operably linked to the polynucleotide described herein.
- Another embodiment described herein relates to a vector comprising the expression cassette described herein.
- Another embodiment described herein relates to a transformed cell comprising the expression cassette or the vector described herein.
- Another embodiment described herein relates to a method for producing an antigen-binding polypeptide, comprising culturing the transformed cell described herein, and isolating the antigen-binding polypeptide expressed by the transformed cell.
- the methods herein relate to the co-delivery of antibiotics with the antigen-binding polypeptide (e.g., monoclonal antibody) described herein.
- the antigen-binding polypeptide e.g., monoclonal antibody
- Additional embodiments described herein relate to a vaccine against Pf-family bacteriophage, comprising (a) an immunogenic fragment of CoaB protein of Pf-family bacteriophage, and (b) a pharmaceutically acceptable excipient.
- the immunogenic fragment of CoaB protein consists of the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO:1)
- FIG. 1 Pf 4 bacteriophage organizes P. aeruginosa biofilms into a liquid crystalline structure.
- Panel A Pf4 production by colony biofilms formed from the indicated strains enumerated as plaque forming units/milliliter (PFU/ml).
- Two versions of the standard PA01 P. aeruginosa lab strain were used: a “rough” strain that produces only a modest biofilm and a small colony variant (SCV) strain that produces robust biofilms.
- strain PA0728 a version of PA01 that does not produce Pf phage, was also used. Adjusted total Pf phage content are also plotted on the right axis. Results are mean ⁇ SD of three experiments.
- Panel B Representative images of rough and SCV colony biofilms showing transmitted light (displayed as I/I O ) and birefringence (jsin(d)j).
- Panel C Birefringence (sin(d)) of the indicated colony biofilms was quantified after normalizing for sample thickness. Birefringence, the capacity of a material to split light into two beams with perpendicular polarization, is a signature characteristic of crystals, Thus, assessments of birefringence can be used to determine whether a biofilm is a crystal. Birefringence was again measured after washing of the bacteria to remove the extracellular matrix. Results are mean ⁇ SD of four experiments.
- Panel D Representative images for SVC and “rough” colony biofilms (placed between glass plates) visualized through crossed polarizing lenses. Birefringence is visualized as bright areas where light passes through both polarizing lenses. The birefringence patterns change when the sample is rotated with respect to the polarizing lenses, revealing extended areas of birefringence. Together, the data in FIG. 1 show that biofilms made by P. aeruginosa are liquid crystals and that this crystalline organization is dependent on the presence of Pf phage.
- FIG. 2 shows that a filamentous bacteriophage, Pf4, contributes to P. aeruginosa biofilm function.
- FIG. 2 shows data describing biofilm characteristics for two strains of P. aeruginosa -PA01 (a standard laboratory strain) and PA0728 (a version of PA01 from which the promoter responsible for Pf4 phage production has been deleted, such that Pf phage production is reduced).
- the Pf phage copy number is shown for P. aeruginosa strains PA01 and PA0728, as measured by quantitative PCR.
- panel B the amount of CoaB protein, the coat protein that surrounds phage, is shown to be reduced in PA0728 versus PA01 by Mass Spectrometry.
- Panel C the amount of P. aeruginosa colony aggregation is shown to be reduced for PA0728 versus PA01.
- Panel D the adhesion of these bacterial colonies is shown for PA0728 versus PA01, as measured in a flow chamber and crystal violet staining.
- Panel E the susceptibility of PA0728 versus PA01 to 10 ⁇ g/ml of the antibiotic gentamycin is shown.
- panel F the birefringence of PA0728 versus PA01 is shown. It has been recently reported that Pf phage contribute to the organization of P. aeruginosa biofilms into a liquid crystal and that this contributes to biofilm adhesion and antibiotic tolerance. Together, the data in FIG. 2 show that the presence of Pf phage contributes to P. aeruginosa biofilm function. These data are further elaborated upon in Secor et al., Cell Host & Microbe., 18(5):549-559 (2015).
- FIG. 3 shows that supplementation of P. aeruginosa strain PA01 with Pf4 bacteriophage makes these colonies more tolerant to multiple antibiotics. Killing is represented as the log 10 reduction of viable cells recovered from cultures treated with different antibiotics, all at 10 mg/ml, compared to untreated controls. Results are mean ⁇ SD of three experiments.
- FIG. 4 shows that serum from rabbits immunized with whole Pf phage prevents biofilm formation. Biofilm formation was assayed by quantification of birefringence (liquid crystal-like organization of the biofilm matrix) of PA01 cultures 18 h after seeding and treatment with serum from rabbits before or after immunization against Pf4 phage.
- birefringence liquid crystal-like organization of the biofilm matrix
- FIG. 5 shows that the addition of secondary antibodies (IgG) to biofilms pre-treated with antiserum undergo aggregation and clumping.
- Serum from rabbits before (pre-serum) or after immunization against Pf4 phage (anti-serum) was added to cultures of a strain of PA01. Then, a fluorescently labeled secondary antibody against rabbit IgG was used to visualize the clustering of bacteria. Confocal microscopy images are shown on the Left side of the image while fluorescence microscopy images are shown on the Right.
- FIG. 6 shows that the addition of secondary antibodies (IgM) to biofilms pre-treated with antiserum undergo aggregation and clumping.
- Serum from rabbits before (pre-serum) or after immunization against Pf4 phage (anti-serum) was added to cultures of P. aeruginosa strain PA01. Then, a fluorescently labeled secondary antibody against rabbit IgM was used to visualize the clustering of bacteria. Confocal microscopy images are shown on the Left side of the image while fluorescence microscopy images are shown on the Right.
- FIG. 7 shows that monoclonal antibody directed against Pf-family bacteriophage disrupt tactoidal (crystalline) structure formation by Pf4-polymer solutions.
- a panel of monoclonal antibodies were generated against the coat protein (CoaB) of Pf4 bacteriophage. All of these monoclonal antibodies had similar effects on tactoidal structures.
- FIG. 8 shows a semi quantitative dot colony-forming assay that demonstrates that the anti-Pf4 monoclonal antibodies facilitate the penetration of antibiotics into biofilms (exposed to 10 ⁇ g/ml of Tobramycin).
- These experiments were performed by adding one of 4 monoclonal antibodies (AB1, AB2, AB3, AB4) that recognize Pf phage or a control antibody that does not recognize pf phage (AB5) to dilutions of biofilm cultures of the PA01 strain of P. aeruginosa .
- the size of the bacterial colonies that grow in this setting is inversely related to the penetration of antibiotic through the biofilm.
- FIG. 9 shows PA concentration survived when exposed to anti-Pf4 antibodies and 10 ⁇ g/ml of Tobramycin. This figure provides quantification of the bacterial killing observed in FIG. 8 .
- FIG. 10 shows a semi quantitative dot colony-forming assay that demonstrates that the anti-Pf4 antibodies facilitate the penetration of antibiotics into biofilms (exposed to 50 ⁇ g/ml of Tobramycin).
- These experiments were performed by adding one of 4 monoclonal antibodies (AB1, AB2, AB3, AB4) that recognize Pf phage or a control antibody that does not recognize pf phage (AB5) to dilutions of biofilm cultures of the PA01 strain of P. aeruginosa .
- the size of the bacterial colonies that grow in this setting is inversely related to the penetration of antibiotic through the biofilm.
- FIG. 10 shows a semi quantitative dot colony-forming assay that demonstrates that the anti-Pf4 antibodies facilitate the penetration of antibiotics into biofilms (exposed to 50 ⁇ g/ml of Tobramycin).
- FIG. 11 shows PA concentration survived when exposed to anti-Pf4 antibodies and 50 ⁇ g/ml of Tobramycin. This figure provides quantification of the bacterial killing observed in FIG. 10 .
- FIG. 12 shows detection of the heavy and light chains of 5 different monoclonal antibodies by Coomassie staining and by Western Blot (WB).
- Three of the antibodies are IgG and two of the antibodies are IgM. All of these antibodies were generated against the Pf phage coat protein sequence GVIDTSAVESAITDGQGDM (SEQ ID NO: 1).
- FIG. 13 shows detection of the CoaB coat protein of Pf bacteriophage by 5 different monoclonal antibodies by Western Blot (WB). Three of the antibodies are IgG and two of the antibodies are IgM. One of the IgM (Ab5) does not recognize Pf4 phage and is included here as a control.
- Pf-family bacteriophage play a heretofore unappreciated role in microbial biofilm formation.
- Monoclonal antibodies or immunizations directed against Pf-family bacteriophage provide protection against biofilm-associated infections with P. aeruginosa and other microbial pathogens.
- P. aeruginosa and other Gram-negative microbial pathogens can be resistant to multiple antibiotics, which is an enormous medical problem.
- monoclonal antibodies and immunizations directed against Pf-family bacteriophage which can prevent biofilm formation by these microbes. Therefore, these monoclonal antibodies are an effective class of antibiotic.
- described herein are monoclonal antibodies (both IgG and IgM) directed against conserved regions on the CoaB coat protein of Pf-family bacteriophage.
- described herein are synthetic peptides of these same conserved regions on the CoaB coat protein that can be used to immunize animals and human beings against Pf-family bacteriophage. Details of the methods and therapeutic agents of the present invention are provided in the following paragraphs.
- One aspect of the present invention relates to a method for treating or preventing P. aeruginosa infection in a human subject, which can be achieved by, for example, reducing or preventing P. aeruginosa biofilm formation.
- the method can comprise, for example, administering to the human subject a composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage.
- the human subject can be administered with, for example, one or more antigen-binding polypeptides as described herein.
- the antigen-binding polypeptide can be, for example, an antibody such as IgG or IgM.
- the antigen-binding polypeptide can bind specifically to, for example, a CoaB protein of Pf-family bacteriophage or fragment thereof.
- the CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage.
- the CoaB protein or fragment thereof can comprise the amino acid sequence of, for example,
- the human subject can be administered with, for example, one or more antibiotics.
- the antibiotics can comprise a known antibiotic against P. aeruginosa , which includes but is not limited to, Aminoglycosides (including for example, tobramycin and gentamicin), Cephalosporins (including ceftazidime), and flouroquinolones (including ciprofloxacin).
- the antibiotics can be administered to the human subject either sequentially or simultaneously with the antigen-binding polypeptides. Without being bound by any theory, it is believed that the antigen-binding polypeptide could reduce or inhibit P. aeruginosa biofilm formation, thereby rendering the P. aeruginosa more susceptible to antibiotics.
- the human subject can be, for example, infected with a P. aeruginosa strain resistant to one or more antibiotics.
- the human subject can be, for example, infected with one or more additional gram negative pathogens.
- the human subject can be, for example, suffering from cystic fibrosis.
- the human subject can be, for example, suffering from burns.
- the human subject can be, for example, suffering from chronic wounds.
- the human subject can be, for example, suffering from chronic rhinosinusitis.
- the human subject can be, for example, suffering from ventilator-associated pneumonia.
- the human subject can be, for example, suffering from catheter-associated urinary tract infections.
- the human subject can be, for example, suffering from septic shock.
- the human subject can be, for example, suffering from gastrointestinal infections.
- the human subject can be administered with, for example, a vaccine against Pf-family bacteriophage, such as Pf4 bacteriophage.
- the vaccine can comprise, for example, an immunogenic fragment of the CoaB protein of Pf-family bacteriophage as described herein.
- the human subject being vaccinated can be, for example, an immune-compromised person, such as a person suffering from AIDS.
- the human subject being vaccinated can be, for example a person over 60 years old, or a person over 65 years old, or a person over 70 years old.
- the vaccination can immunize the human subject against, for example, P. aeruginosa biofilm formation.
- the vaccination can immunize the human subject against, for example, P. aeruginosa infection.
- Another aspect of the present invention relates to an antigen-binding polypeptide that binds specifically to CoaB protein of Pf-family bacteriophage or fragment thereof.
- the CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage.
- the CoaB protein or fragment thereof can comprise the amino acid sequence of, for example,
- the antigen-binding polypeptide can be, for example, a monoclonal antibody, a chimeric antibody, a humanized antibody, a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, or an scFv molecule.
- the process for making antigen-binding polypeptides are described in, for example, WO/2008/094942, WO/2009/064854, and WO/2010/111180, which are incorporated by reference in their entireties.
- the process comprises (a) immunizing a host with an immunogenic polypeptide of a Pf-family bacteriophage, such as an immunogenic fragment of the CoaB protein of Pf4 bacteriophage; and (b) harvesting the resulting antibody against the immunogenic polypeptide.
- an immunogenic polypeptide of a Pf-family bacteriophage such as an immunogenic fragment of the CoaB protein of Pf4 bacteriophage
- the antigen-binding polypeptide can be, for example, part of a fusion molecule.
- the fusion molecule can comprise, for example, a therapeutic or diagnostic agent conjugated to the antigen-binding polypeptide, as described in WO/2008/094942, WO/2009/064854, and WO/2010/111180.
- the monoclonal antibodies can also be functionalized to better disrupt biofilms.
- the functionalized monoclonal antibodies can comprise, for example, enzymes that degrade constituents of the biofilm matrix, such as DNase I or alginate lyase, or charged molecules such as QDOTs or latex beads intended to alter the tertiary structure of the biofilm matrix.
- Functionalization can also consist of antibiotics, opsonins, reporter molecules, adjuvants, immunogens, or other proteins, carbohydrates or lipids conjugated to the antibodies.
- the antigen-binding polypeptide is an anti-Pf4 monoclonal antibody or fragment thereof.
- the monoclonal antibody or fragment thereof specifically binds to the CoaB protein of Pf4 bacteriophage.
- the monoclonal antibody or fragment thereof specifically binds to an antigenic fragment of the CoaB protein comprising, consisting essentially of or consisting of the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO:1).
- the monoclonal antibody or fragment thereof has a humanized heavy chain variable region and a humanized light chain variable region.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of WQGTHFPQT (SEQ ID NO: 11).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPWT (SEQ ID NO: 21).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPFT (SEQ ID NO: 31).
- the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the
- the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVASISSGGSTYY PDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQDYGAAYWGQGTLVTVSA (SEQ ID NO: 2) or a humanized version thereof.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGAIYPGNSD TSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQFYSGSSEDAMDYWGQ GTSVTVSS (SEQ ID NO: 12) or a humanized version thereof.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGWINTNTGEP TYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKDYRYWFAYWGQGTLVTV SA (SEQ ID NO: 22) or a humanized version thereof.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLD SGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK (SEQ ID NO: 4) or a humanized version thereof.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPWTFGGGTKLEIK (SEQ ID NO: 14) or a humanized version thereof.
- the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 24) or a humanized version thereof.
- Another aspect of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) the antigen-binding polypeptide described herein or a fusion molecule comprising the antigen-binding polypeptide, and (b) a pharmaceutically acceptable carrier.
- the active ingredient of the pharmaceutical composition consists essentially of the antigen-binding polypeptide or fusion molecule.
- the active ingredient of the pharmaceutical composition consists of the antigen-binding polypeptide or fusion molecule.
- polynucleotide encoding the antigen-binding polypeptide described herein can be comprised in, for example, an expression cassette, with optionally a promoter operably linked to the polynucleotide.
- the expression cassette can be comprised in, for example, a plasmid or transformation vector.
- the plasmid or transformation vector can be used to obtain a transformed cell capable of producing the antigen-binding polypeptide encoded therein.
- the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
- the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of WQGTHFPQ
- the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of F
- the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSH
- the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVASISSGGSTYY PDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQDYGAAYWGQGTLVTVSA (SEQ ID NO: 2) or a humanized version thereof.
- the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGAIYPGNSD TSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQFYSGSSEDAMDYWGQ GTSVTVSS (SEQ ID NO: 12) or a humanized version thereof.
- the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGWINTNTGEP TYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKDYRYWFAYWGQGTLVTV SA (SEQ ID NO: 22) or a humanized version thereof.
- the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLD SGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK (SEQ ID NO: 4) or a humanized version thereof.
- the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPWTFGGGTKLEIK (SEQ ID NO: 14) or a humanized version thereof.
- the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 24) or a humanized version thereof.
- a further aspect of the present invention relates to a vaccine against Pf-family bacteriophage, comprising an immunogenic fragment of the CoaB protein of Pf-family bacteriophage.
- the CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage.
- the CoaB protein or fragment thereof can comprise the amino acid sequence of, for example, GVIDTSAVESAITDGQGDM (SEQ ID NO:1).
- the vaccine is used to vaccinate patients newly diagnosed with cystic fibrosis before they become colonized with P. aeruginosa or to elderly people before they become prone to catheter infections and hospital-acquired infections.
- the vaccine is used to vaccinate nursing home populations, or patients undergoing dialysis, mechanical ventilation or recurrent UTIs, or burn victims.
- Filamentous bacteriophage are produced by P. aeruginosa during the biofilm mode of growth (see Rice et al., The ISME Journal (2009) 3, 271-282).
- a mutant not capable of producing Pf4, PA0728 ( FIGS. 2A and 2B ) (see Castang and Dove, J Bacteriol. September 2012; 194(18): 5101-5109), exhibited differences in morphology ( FIG. 2C ), adhesion ( FIG. 2D ), antibiotic susceptibility ( FIG. 2E ), and matrix organization (birefringence, FIG. 2F ).
- the method of preventing biofilm formation by creating vaccines and monoclonal antibodies that target Pf bacteriophage was evaluated. Specifically, rabbits were immunized with CoaB peptide, and the ability of their sera to neutralize biofilm formation was examined. This antiserum was found to inhibit biofilm formation, alter antibiotic tolerance ( FIG. 3 ), and alter the overall organization of the biofilm matrix (reduced birefringence, FIG. 4 ), suggesting that anti-CoaB antibodies present in the serum are capable of disrupting P. aeruginosa biofilms producing the filamentous bacteriophage Pf4.
- the addition of secondary antibodies e.g., fluorescently labeled anti-rabbit IgG and IgM
- P. aeruginosa biofilms pre-treated with anti-Pf4 antibodies altered the gross morphology of P. aeruginosa biofilms ( FIGS. 5 and 6 ).
- the CoaB peptide in question was conjugated to immunogenic proteins in order to elicit an immune response in rabbits and/or mice.
- Clones were then isolated from individual animals with strong serum responses to the peptide in question and these were fused to competent cells to generate hybridomas. These were then grown in culture and monoclonal antibodies were harvested from the cell culture supernatants. The specificity of these against CoaB peptide was then confirmed and five clones with the greatest specificity were selected for further development.
- variable regions of the three mouse IgG anti-Pf4 monoclonal antibodies were sequenced.
- the VH, VL, and CDR sequences of IgG Ab #1 (1A8), IgG Ab #2 (2D4) and IgG Ab #3 (3D6) are provided below.
- IgG Ab #1 VH (SEQ ID NO: 2) EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQD YGAAYWGQGTLVTVSA.
- IgG Ab #1 VL (SEQ ID NO: 4) DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFP QTFGGGTKLEIK.
- IgG Ab #1 CDR: (SEQ ID NO: 6) CDR-H1 - GFTFSSYV. (SEQ ID NO: 7) CDR-H2 - ISSGGST. (SEQ ID NO: 8) CDR-H3 - LRGQDYGAAY. (SEQ ID NO: 9) CDR-L1 - QSLLDSDGKTY. (SEQ ID NO: 10) CDR-L2 - LVS. (SEQ ID NO: 11) CDR-L3 - WQGTHFPQT.
- IgG Ab #2 VH (SEQ ID NO: 12) EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGA IYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQ FYSGSSEDAMDYWGQGTSVTVSS.
- VL (SEQ ID NO: 14) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVP WTFGGGTKLEIK.
- IgG Ab #2 CDR: (SEQ ID NO: 16) CDR-H1 - GYSFTSYW. (SEQ ID NO: 17) CDR-H2 - IYPGNSDT. (SEQ ID NO: 18) CDR-H3 - TRSQFYSGSSEDAMDY. (SEQ ID NO: 19) CDR-L1 - QSIVHSNGNTY. (SEQ ID NO: 20) CDR-L2 - KVS. (SEQ ID NO: 21) CDR-L3 - FQGSHVPWT.
- IgG Ab #3 VH (SEQ ID NO: 22) QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGW INTNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKD YRYWFAYWGQGTLVTVSA.
- VL (SEQ ID NO: 24) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVP FTFGSGTKLEIK.
- Example 2 Also tested is whether the monoclonal antibodies produced according to Example 2 can serve as effective antibiotic drugs that could be used in conjunction with conventional antibiotics, as current therapeutic options for treatment of multidrug-resistant P. aeruginosa are very limited. As shown in FIG. 7 , the mAbs prevented liquid crystal formation of Pf4-polymer solutions suggesting that the mAbs have the same activities as the anti-Pf4 antibodies present in the antiserum of Example 2.
- the terms “substantially,” “substantial,” and “about” are used to describe and account for small variations.
- the terms can refer to instances in which the event or circumstance occurs precisely as well as instances in which the event or circumstance occurs to a close approximation.
- the terms can refer to less than or equal to ⁇ 10%, such as less than or equal to ⁇ 5%, less than or equal to ⁇ 4%, less than or equal to ⁇ 3%, less than or equal to ⁇ 2%, less than or equal to ⁇ 1%, less than or equal to ⁇ 0.5%, less than or equal to ⁇ 0.1%, or less than or equal to ⁇ 0.05%.
- range format is used for convenience and brevity and should be understood flexibly to include numerical values explicitly specified as limits of a range, but also to include all individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly specified.
- a ratio in the range of about 1 to about 200 should be understood to include the explicitly recited limits of about 1 and about 200, but also to include individual ratios such as about 2, about 3, and about 4, and sub-ranges such as about 10 to about 50, about 20 to about 100, and so forth.
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 62/196,147 filed Jul. 23, 2015, the content of which is incorporated herein by reference in its entirety.
- This invention was made with Government support under contract HL007287 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- Pseudomonas aeruginosa is an opportunistic pathogen in multiple clinical settings, including devastating pulmonary infections in individuals with the genetic disorder cystic fibrosis (CF). The virulence of P. aeruginosa is predicated on its ability to form biofilms, which are organized communities of bacteria encased in a polymer-rich matrix. Bacterial biofilms are ubiquitous in nature, and they endow bacteria with the ability to resist antibiotics and evade host immune defense mechanisms. See Costerton et al., Science 284:1318 (1999); Stewart et al., Int. J. Med. Microbiol. 292:107 (2002).
- Thus, a need exists to develop therapeutic agents that can inhibit the formation of P. aeruginosa biofilms thereby making P. aeruginosa infections more susceptible to antibiotic treatment.
- Many embodiments described herein relate to a method for reducing or preventing P. aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage.
- In one embodiment, the first composition comprises an antigen-binding polypeptide. In one embodiment, the antigen-binding polypeptide binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof. In one embodiment, the antigen-binding polypeptide is IgG or IgM.
- In one embodiment, the first composition further comprises an antibiotic, or the method further comprises administering a second composition comprising an antibiotic to the human subject.
- In one embodiment, the human subject is infected with a P. aeruginosa strain resistant to one or more antibiotics.
- In one embodiment, the first composition comprises a vaccine against Pf-family bacteriophage. In one embodiment, the vaccine comprises an immunogenic fragment of Pf-family bacteriophage.
- In one embodiment, the CoaB protein or fragment thereof comprises the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO: 1).
- In one embodiment, the human subject is suffering from cystic fibrosis, burns, chronic would, chronic rhinosinusitis, ventilator-associated pneumonia, catheter-associated urinary tract infections, septic shock, and/or gastrointestinal infections.
- Further embodiments described herein relate to an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
- In one embodiment, the antigen-binding polypeptide specifically binds to an antigenic fragment of the CoaB protein comprising the amino acid sequence of
-
GVIDTSAVESAITDGQGDM. (SEQ ID NO: 1) - In one embodiment, the antigen-binding polypeptide is a monoclonal antibody, a chimeric antibody, a humanized antibody, a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, or an scFv molecule. In one embodiment, the antigen-binding polypeptide is IgG or IgM.
- Another embodiment described herein relates to a pharmaceutical composition comprising (a) the antigen-binding polypeptide described herein or a fusion molecule comprising the antigen-binding polypeptide, and (b) a pharmaceutically acceptable carrier.
- Another embodiment described herein relates to a polynucleotide encoding the antigen-binding polypeptide described herein.
- Another embodiment described herein relates to an expression cassette comprising a promoter operably linked to the polynucleotide described herein.
- Another embodiment described herein relates to a vector comprising the expression cassette described herein.
- Another embodiment described herein relates to a transformed cell comprising the expression cassette or the vector described herein.
- Another embodiment described herein relates to a method for producing an antigen-binding polypeptide, comprising culturing the transformed cell described herein, and isolating the antigen-binding polypeptide expressed by the transformed cell.
- In one embodiment, the methods herein relate to the co-delivery of antibiotics with the antigen-binding polypeptide (e.g., monoclonal antibody) described herein.
- Additional embodiments described herein relate to a vaccine against Pf-family bacteriophage, comprising (a) an immunogenic fragment of CoaB protein of Pf-family bacteriophage, and (b) a pharmaceutically acceptable excipient.
- In one embodiment, the immunogenic fragment of CoaB protein consists of the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO:1)
- These and other features, together with the organization and manner of operation thereof, will become apparent from the following detailed description when taken in conjunction with the accompanying drawings.
-
FIG. 1 .Pf 4 bacteriophage organizes P. aeruginosa biofilms into a liquid crystalline structure. Panel A: Pf4 production by colony biofilms formed from the indicated strains enumerated as plaque forming units/milliliter (PFU/ml). Two versions of the standard PA01 P. aeruginosa lab strain were used: a “rough” strain that produces only a modest biofilm and a small colony variant (SCV) strain that produces robust biofilms. In addition, strain PA0728, a version of PA01 that does not produce Pf phage, was also used. Adjusted total Pf phage content are also plotted on the right axis. Results are mean±SD of three experiments. Panel B: Representative images of rough and SCV colony biofilms showing transmitted light (displayed as I/IO) and birefringence (jsin(d)j). Panel C: Birefringence (sin(d)) of the indicated colony biofilms was quantified after normalizing for sample thickness. Birefringence, the capacity of a material to split light into two beams with perpendicular polarization, is a signature characteristic of crystals, Thus, assessments of birefringence can be used to determine whether a biofilm is a crystal. Birefringence was again measured after washing of the bacteria to remove the extracellular matrix. Results are mean±SD of four experiments. Panel D: Representative images for SVC and “rough” colony biofilms (placed between glass plates) visualized through crossed polarizing lenses. Birefringence is visualized as bright areas where light passes through both polarizing lenses. The birefringence patterns change when the sample is rotated with respect to the polarizing lenses, revealing extended areas of birefringence. Together, the data inFIG. 1 show that biofilms made by P. aeruginosa are liquid crystals and that this crystalline organization is dependent on the presence of Pf phage. -
FIG. 2 shows that a filamentous bacteriophage, Pf4, contributes to P. aeruginosa biofilm function.FIG. 2 shows data describing biofilm characteristics for two strains of P. aeruginosa-PA01 (a standard laboratory strain) and PA0728 (a version of PA01 from which the promoter responsible for Pf4 phage production has been deleted, such that Pf phage production is reduced). In panel A, the Pf phage copy number is shown for P. aeruginosa strains PA01 and PA0728, as measured by quantitative PCR. In panel B the amount of CoaB protein, the coat protein that surrounds phage, is shown to be reduced in PA0728 versus PA01 by Mass Spectrometry. In Panel C, the amount of P. aeruginosa colony aggregation is shown to be reduced for PA0728 versus PA01. In Panel D, the adhesion of these bacterial colonies is shown for PA0728 versus PA01, as measured in a flow chamber and crystal violet staining. In Panel E, the susceptibility of PA0728 versus PA01 to 10 μg/ml of the antibiotic gentamycin is shown. In panel F, the birefringence of PA0728 versus PA01 is shown. It has been recently reported that Pf phage contribute to the organization of P. aeruginosa biofilms into a liquid crystal and that this contributes to biofilm adhesion and antibiotic tolerance. Together, the data inFIG. 2 show that the presence of Pf phage contributes to P. aeruginosa biofilm function. These data are further elaborated upon in Secor et al., Cell Host & Microbe., 18(5):549-559 (2015). -
FIG. 3 shows that supplementation of P. aeruginosa strain PA01 with Pf4 bacteriophage makes these colonies more tolerant to multiple antibiotics. Killing is represented as the log10 reduction of viable cells recovered from cultures treated with different antibiotics, all at 10 mg/ml, compared to untreated controls. Results are mean±SD of three experiments. -
FIG. 4 shows that serum from rabbits immunized with whole Pf phage prevents biofilm formation. Biofilm formation was assayed by quantification of birefringence (liquid crystal-like organization of the biofilm matrix) of PA01 cultures 18 h after seeding and treatment with serum from rabbits before or after immunization against Pf4 phage. -
FIG. 5 shows that the addition of secondary antibodies (IgG) to biofilms pre-treated with antiserum undergo aggregation and clumping. Serum from rabbits before (pre-serum) or after immunization against Pf4 phage (anti-serum) was added to cultures of a strain of PA01. Then, a fluorescently labeled secondary antibody against rabbit IgG was used to visualize the clustering of bacteria. Confocal microscopy images are shown on the Left side of the image while fluorescence microscopy images are shown on the Right. -
FIG. 6 shows that the addition of secondary antibodies (IgM) to biofilms pre-treated with antiserum undergo aggregation and clumping. Serum from rabbits before (pre-serum) or after immunization against Pf4 phage (anti-serum) was added to cultures of P. aeruginosa strain PA01. Then, a fluorescently labeled secondary antibody against rabbit IgM was used to visualize the clustering of bacteria. Confocal microscopy images are shown on the Left side of the image while fluorescence microscopy images are shown on the Right. -
FIG. 7 shows that monoclonal antibody directed against Pf-family bacteriophage disrupt tactoidal (crystalline) structure formation by Pf4-polymer solutions. For these experiments, a panel of monoclonal antibodies were generated against the coat protein (CoaB) of Pf4 bacteriophage. All of these monoclonal antibodies had similar effects on tactoidal structures. -
FIG. 8 shows a semi quantitative dot colony-forming assay that demonstrates that the anti-Pf4 monoclonal antibodies facilitate the penetration of antibiotics into biofilms (exposed to 10 μg/ml of Tobramycin). These experiments were performed by adding one of 4 monoclonal antibodies (AB1, AB2, AB3, AB4) that recognize Pf phage or a control antibody that does not recognize pf phage (AB5) to dilutions of biofilm cultures of the PA01 strain of P. aeruginosa. The size of the bacterial colonies that grow in this setting is inversely related to the penetration of antibiotic through the biofilm. -
FIG. 9 shows PA concentration survived when exposed to anti-Pf4 antibodies and 10 μg/ml of Tobramycin. This figure provides quantification of the bacterial killing observed inFIG. 8 . -
FIG. 10 shows a semi quantitative dot colony-forming assay that demonstrates that the anti-Pf4 antibodies facilitate the penetration of antibiotics into biofilms (exposed to 50 μg/ml of Tobramycin). These experiments were performed by adding one of 4 monoclonal antibodies (AB1, AB2, AB3, AB4) that recognize Pf phage or a control antibody that does not recognize pf phage (AB5) to dilutions of biofilm cultures of the PA01 strain of P. aeruginosa. The size of the bacterial colonies that grow in this setting is inversely related to the penetration of antibiotic through the biofilm. Compared toFIG. 8 , these data show that the effect of the antibodies was more intense when the biofilms were exposed to higher concentration of Tobramycin (50 ug/ml compared to 10 ug/ml). In that case AB1 and AB2 cause to 7 orders of magnitude reduction in P. aeruginosa. concentration that survived the Tobramycin treatment compare to the control. -
FIG. 11 shows PA concentration survived when exposed to anti-Pf4 antibodies and 50 μg/ml of Tobramycin. This figure provides quantification of the bacterial killing observed inFIG. 10 . -
FIG. 12 shows detection of the heavy and light chains of 5 different monoclonal antibodies by Coomassie staining and by Western Blot (WB). Three of the antibodies are IgG and two of the antibodies are IgM. All of these antibodies were generated against the Pf phage coat protein sequence GVIDTSAVESAITDGQGDM (SEQ ID NO: 1). -
FIG. 13 shows detection of the CoaB coat protein of Pf bacteriophage by 5 different monoclonal antibodies by Western Blot (WB). Three of the antibodies are IgG and two of the antibodies are IgM. One of the IgM (Ab5) does not recognize Pf4 phage and is included here as a control. - Pf-family bacteriophage play a heretofore unappreciated role in microbial biofilm formation. Monoclonal antibodies or immunizations directed against Pf-family bacteriophage provide protection against biofilm-associated infections with P. aeruginosa and other microbial pathogens. In particular, P. aeruginosa and other Gram-negative microbial pathogens can be resistant to multiple antibiotics, which is an enormous medical problem. Described herein are monoclonal antibodies and immunizations directed against Pf-family bacteriophage which can prevent biofilm formation by these microbes. Therefore, these monoclonal antibodies are an effective class of antibiotic.
- In some embodiments, described herein are monoclonal antibodies (both IgG and IgM) directed against conserved regions on the CoaB coat protein of Pf-family bacteriophage. In other embodiments, described herein are synthetic peptides of these same conserved regions on the CoaB coat protein that can be used to immunize animals and human beings against Pf-family bacteriophage. Details of the methods and therapeutic agents of the present invention are provided in the following paragraphs.
- Method for Treating/Preventing P. aeruginosa Infection
- One aspect of the present invention relates to a method for treating or preventing P. aeruginosa infection in a human subject, which can be achieved by, for example, reducing or preventing P. aeruginosa biofilm formation. The method can comprise, for example, administering to the human subject a composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage.
- The human subject can be administered with, for example, one or more antigen-binding polypeptides as described herein. The antigen-binding polypeptide can be, for example, an antibody such as IgG or IgM. The antigen-binding polypeptide can bind specifically to, for example, a CoaB protein of Pf-family bacteriophage or fragment thereof. The CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage. The CoaB protein or fragment thereof can comprise the amino acid sequence of, for example,
-
GVIDTSAVESAITDGQGDM. (SEQ ID NO: 1) - The human subject can be administered with, for example, one or more antibiotics. The antibiotics can comprise a known antibiotic against P. aeruginosa, which includes but is not limited to, Aminoglycosides (including for example, tobramycin and gentamicin), Cephalosporins (including ceftazidime), and flouroquinolones (including ciprofloxacin). The antibiotics can be administered to the human subject either sequentially or simultaneously with the antigen-binding polypeptides. Without being bound by any theory, it is believed that the antigen-binding polypeptide could reduce or inhibit P. aeruginosa biofilm formation, thereby rendering the P. aeruginosa more susceptible to antibiotics.
- The human subject can be, for example, infected with a P. aeruginosa strain resistant to one or more antibiotics. The human subject can be, for example, infected with one or more additional gram negative pathogens.
- The human subject can be, for example, suffering from cystic fibrosis. The human subject can be, for example, suffering from burns. The human subject can be, for example, suffering from chronic wounds. The human subject can be, for example, suffering from chronic rhinosinusitis. The human subject can be, for example, suffering from ventilator-associated pneumonia. The human subject can be, for example, suffering from catheter-associated urinary tract infections. The human subject can be, for example, suffering from septic shock. The human subject can be, for example, suffering from gastrointestinal infections.
- The human subject can be administered with, for example, a vaccine against Pf-family bacteriophage, such as Pf4 bacteriophage. The vaccine can comprise, for example, an immunogenic fragment of the CoaB protein of Pf-family bacteriophage as described herein.
- The human subject being vaccinated can be, for example, an immune-compromised person, such as a person suffering from AIDS. The human subject being vaccinated can be, for example a person over 60 years old, or a person over 65 years old, or a person over 70 years old.
- The vaccination can immunize the human subject against, for example, P. aeruginosa biofilm formation. The vaccination can immunize the human subject against, for example, P. aeruginosa infection.
- Antibody Against Pf-Family Bacteriophage
- Another aspect of the present invention relates to an antigen-binding polypeptide that binds specifically to CoaB protein of Pf-family bacteriophage or fragment thereof. The CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage. The CoaB protein or fragment thereof can comprise the amino acid sequence of, for example,
-
GVIDTSAVESAITDGQGDM. (SEQ ID NO: 1) - The antigen-binding polypeptide can be, for example, a monoclonal antibody, a chimeric antibody, a humanized antibody, a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, or an scFv molecule. The process for making antigen-binding polypeptides are described in, for example, WO/2008/094942, WO/2009/064854, and WO/2010/111180, which are incorporated by reference in their entireties. In one embodiment, the process comprises (a) immunizing a host with an immunogenic polypeptide of a Pf-family bacteriophage, such as an immunogenic fragment of the CoaB protein of Pf4 bacteriophage; and (b) harvesting the resulting antibody against the immunogenic polypeptide.
- The antigen-binding polypeptide can be, for example, part of a fusion molecule. The fusion molecule can comprise, for example, a therapeutic or diagnostic agent conjugated to the antigen-binding polypeptide, as described in WO/2008/094942, WO/2009/064854, and WO/2010/111180.
- The monoclonal antibodies can also be functionalized to better disrupt biofilms. The functionalized monoclonal antibodies can comprise, for example, enzymes that degrade constituents of the biofilm matrix, such as DNase I or alginate lyase, or charged molecules such as QDOTs or latex beads intended to alter the tertiary structure of the biofilm matrix. Functionalization can also consist of antibiotics, opsonins, reporter molecules, adjuvants, immunogens, or other proteins, carbohydrates or lipids conjugated to the antibodies.
- In some embodiments, the antigen-binding polypeptide is an anti-Pf4 monoclonal antibody or fragment thereof. In some embodiments, the monoclonal antibody or fragment thereof specifically binds to the CoaB protein of Pf4 bacteriophage. In some embodiments, the monoclonal antibody or fragment thereof specifically binds to an antigenic fragment of the CoaB protein comprising, consisting essentially of or consisting of the amino acid sequence of GVIDTSAVESAITDGQGDM (SEQ ID NO:1). In some embodiments, the monoclonal antibody or fragment thereof has a humanized heavy chain variable region and a humanized light chain variable region.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of WQGTHFPQT (SEQ ID NO: 11).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPWT (SEQ ID NO: 21).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPFT (SEQ ID NO: 31).
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
WQGTHFPQT. (SEQ ID NO: 11) - In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
FQGSHVPWT. (SEQ ID NO: 21) - In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
FQGSHVPFT. (SEQ ID NO: 31) - In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVASISSGGSTYY PDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQDYGAAYWGQGTLVTVSA (SEQ ID NO: 2) or a humanized version thereof.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGAIYPGNSD TSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQFYSGSSEDAMDYWGQ GTSVTVSS (SEQ ID NO: 12) or a humanized version thereof.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGWINTNTGEP TYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKDYRYWFAYWGQGTLVTV SA (SEQ ID NO: 22) or a humanized version thereof.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLD SGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK (SEQ ID NO: 4) or a humanized version thereof.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPWTFGGGTKLEIK (SEQ ID NO: 14) or a humanized version thereof.
- In some embodiments, the anti-Pf4 monoclonal antibody or fragment thereof comprises a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 24) or a humanized version thereof.
- Another aspect of the present invention relates to a pharmaceutical composition comprising (a) the antigen-binding polypeptide described herein or a fusion molecule comprising the antigen-binding polypeptide, and (b) a pharmaceutically acceptable carrier. In one embodiment, the active ingredient of the pharmaceutical composition consists essentially of the antigen-binding polypeptide or fusion molecule. In another embodiment, the active ingredient of the pharmaceutical composition consists of the antigen-binding polypeptide or fusion molecule.
- Another aspect of the present invention relates to a polynucleotide encoding the antigen-binding polypeptide described herein. The polynucleotide encoding the antigen-binding polypeptide can be comprised in, for example, an expression cassette, with optionally a promoter operably linked to the polynucleotide. The expression cassette can be comprised in, for example, a plasmid or transformation vector. The plasmid or transformation vector can be used to obtain a transformed cell capable of producing the antigen-binding polypeptide encoded therein.
- In some embodiments, the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
LRGQDYGAAY. (SEQ ID NO: 8) - In some embodiments, the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
TRSQFYSGSSEDAMDY. (SEQ ID NO: 18) - In some embodiments, the polynucleotide encodes a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
ARKDYRYWFAY. (SEQ ID NO: 28) - In some embodiments, the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
WQGTHFPQT. (SEQ ID NO: 11) - In some embodiments, the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
FQGSHVPWT. (SEQ ID NO: 21) - In some embodiments, the polynucleotide encodes a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of
-
FQGSHVPFT. (SEQ ID NO: 31) - In some embodiments, the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GFTFSSYV (SEQ ID NO: 6); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of ISSGGST (SEQ ID NO: 7); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of LRGQDYGAAY (SEQ ID NO: 8), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 9); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of LVS (SEQ ID NO: 10); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of WQGTHFPQT (SEQ ID NO: 11).
- In some embodiments, the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYSFTSYW (SEQ ID NO: 16); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of IYPGNSDT (SEQ ID NO: 17); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO: 18), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 19); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 20); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPWT (SEQ ID NO: 21).
- In some embodiments, the polynucleotide encodes (a) a heavy chain variable region comprising (1) the CDR-H1 comprising, consisting essentially of or consisting of the amino acid sequence of GYTFTNYG (SEQ ID NO: 26); (2) the CDR-H2 comprising, consisting essentially of or consisting of the amino acid sequence of INTNTGEP (SEQ ID NO: 27); and (3) the CDR-H3 comprising, consisting essentially of or consisting of the amino acid sequence of ARKDYRYWFAY (SEQ ID NO: 28), and (b) a light chain variable region comprising (1) the CDR-L1 comprising, consisting essentially of or consisting of the amino acid sequence of QSIVHSNGNTY (SEQ ID NO: 29); (2) the CDR-L2 comprising, consisting essentially of or consisting of the amino acid sequence of KVS (SEQ ID NO: 30); and (3) the CDR-L3 comprising, consisting essentially of or consisting of the amino acid sequence of FQGSHVPFT (SEQ ID NO: 31).
- In some embodiments, the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVASISSGGSTYY PDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQDYGAAYWGQGTLVTVSA (SEQ ID NO: 2) or a humanized version thereof.
- In some embodiments, the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGAIYPGNSD TSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQFYSGSSEDAMDYWGQ GTSVTVSS (SEQ ID NO: 12) or a humanized version thereof.
- In some embodiments, the polynucleotide encodes a heavy chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGWINTNTGEP TYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKDYRYWFAYWGQGTLVTV SA (SEQ ID NO: 22) or a humanized version thereof.
- In some embodiments, the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLD SGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK (SEQ ID NO: 4) or a humanized version thereof.
- In some embodiments, the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPWTFGGGTKLEIK (SEQ ID NO: 14) or a humanized version thereof.
- In some embodiments, the polynucleotide encodes a light chain variable region comprising, consisting essentially of or consisting of the amino acid sequence of DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 24) or a humanized version thereof.
- Vaccine Against Pf-Family Bacteriophage
- A further aspect of the present invention relates to a vaccine against Pf-family bacteriophage, comprising an immunogenic fragment of the CoaB protein of Pf-family bacteriophage. The CoaB protein or fragment thereof can be, for example, the CoaB protein of Pf4 bacteriophage. The CoaB protein or fragment thereof can comprise the amino acid sequence of, for example, GVIDTSAVESAITDGQGDM (SEQ ID NO:1).
- In some embodiments, the vaccine is used to vaccinate patients newly diagnosed with cystic fibrosis before they become colonized with P. aeruginosa or to elderly people before they become prone to catheter infections and hospital-acquired infections. In some embodiments, the vaccine is used to vaccinate nursing home populations, or patients undergoing dialysis, mechanical ventilation or recurrent UTIs, or burn victims.
- These and other features, together with the organization and manner of operation thereof, will become apparent from the following detailed description when taken in conjunction with the accompanying drawings.
- It has been recently reported that a bacteriophage/virus produced by the bacteria Pseudomonas aeruginosa contributes to the formation and function of Pseudomonas aeruginosa biofilms. In particular, it has been reported that Pf bacteriophage assemble biofilms into a liquid crystal and that this crystalline organization contributes to biofilm function, including adhesiveness and antibiotic tolerance. See Secor et al., Cell Host & Microbe., 18(5):549-559 (2015). In light of these data implicating Pf bacteriophages in biofilm structure and function, vaccines and monoclonal antibodies that target Pf bacteriophages have been generated to disrupt Pseudomonas aeruginosa biofilms.
- Filamentous bacteriophage are produced by P. aeruginosa during the biofilm mode of growth (see Rice et al., The ISME Journal (2009) 3, 271-282). A mutant not capable of producing Pf4, PA0728 (
FIGS. 2A and 2B ) (see Castang and Dove, J Bacteriol. September 2012; 194(18): 5101-5109), exhibited differences in morphology (FIG. 2C ), adhesion (FIG. 2D ), antibiotic susceptibility (FIG. 2E ), and matrix organization (birefringence,FIG. 2F ). - The method of preventing biofilm formation by creating vaccines and monoclonal antibodies that target Pf bacteriophage was evaluated. Specifically, rabbits were immunized with CoaB peptide, and the ability of their sera to neutralize biofilm formation was examined. This antiserum was found to inhibit biofilm formation, alter antibiotic tolerance (
FIG. 3 ), and alter the overall organization of the biofilm matrix (reduced birefringence,FIG. 4 ), suggesting that anti-CoaB antibodies present in the serum are capable of disrupting P. aeruginosa biofilms producing the filamentous bacteriophage Pf4. The addition of secondary antibodies (e.g., fluorescently labeled anti-rabbit IgG and IgM) to P. aeruginosa biofilms pre-treated with anti-Pf4 antibodies altered the gross morphology of P. aeruginosa biofilms (FIGS. 5 and 6 ). - Monoclonal antibodies that target Pf4, including three IgG and two IgM antibodies, were developed as a new class of anti-microbial for use against multi-drug resistant P. aeruginosa. These antibodies were generated using standard, well-established techniques, generally as described in http://www.currentprotocols.com/WileyCDA/CPUnit/refIdim0205.html. In brief, the CoaB peptide in question was conjugated to immunogenic proteins in order to elicit an immune response in rabbits and/or mice. Clones were then isolated from individual animals with strong serum responses to the peptide in question and these were fused to competent cells to generate hybridomas. These were then grown in culture and monoclonal antibodies were harvested from the cell culture supernatants. The specificity of these against CoaB peptide was then confirmed and five clones with the greatest specificity were selected for further development.
- The variable regions of the three mouse IgG anti-Pf4 monoclonal antibodies were sequenced. The VH, VL, and CDR sequences of IgG Ab #1 (1A8), IgG Ab #2 (2D4) and IgG Ab #3 (3D6) are provided below.
-
IgG Ab # 1 VH:(SEQ ID NO: 2) EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYVMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCLRGQD YGAAYWGQGTLVTVSA. (SEQ ID NO: 3) GAAGTGAAGCTGGTGGAGTCTGGGGGAGACTTAGTGAAGCCTGGAGGGTC CCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATGTCA TGTCTTGGGTTCGCCAGACTCCAGAAAAGAGGCTGGAGTGGGTCGCATCC ATTAGTAGTGGTGGTAGCACCTACTATCCAGACAGTGTGAAGGGCCGATT CACCATCTCCAGAGATAATGCCAGGAACATCCTGTACCTGCAAATGAGTA GTCTGAGGTCTGAGGACACGGCCATGTATTACTGTTTAAGAGGCCAGGAC TACGGCGCCGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA. IgG Ab # 1 VL:(SEQ ID NO: 4) DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFP QTFGGGTKLEIK. (SEQ ID NO: 5) GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACCATTGGACA ACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAGATAGTGATG GAAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCTCCAAAG CGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTT CACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTGG AGGCTGAGGATTTGGGAGTTTATTATTGCTGGCAAGGTACACATTTTCCT CAGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA. IgG Ab # 1 CDR:(SEQ ID NO: 6) CDR-H1 - GFTFSSYV. (SEQ ID NO: 7) CDR-H2 - ISSGGST. (SEQ ID NO: 8) CDR-H3 - LRGQDYGAAY. (SEQ ID NO: 9) CDR-L1 - QSLLDSDGKTY. (SEQ ID NO: 10) CDR-L2 - LVS. (SEQ ID NO: 11) CDR-L3 - WQGTHFPQT. IgG Ab # 2 VH:(SEQ ID NO: 12) EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGA IYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSCLTNEDSAVFYCTRSQ FYSGSSEDAMDYWGQGTSVTVSS. (SEQ ID NO: 13) GAGGTTCAGCTCCAGCAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTC CGTGAAGATGTCCTGCAAGGCTTCTGGCTACAGCTTTACCAGCTACTGGA TGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTAGAATGGATTGGTGCT ATTTATCCTGGAAATAGTGATACTAGTTACAACCAGAAGTTCAAGGGCAA GGCCAAACTGACTGCAGTCACATCCGCCAGCACTGCCTACATGGAGCTCA GCTGCCTGACAAATGAGGACTCTGCGGTCTTTTACTGTACAAGATCCCAA TTTTACTCCGGTAGTAGCGAGGATGCTATGGACTACTGGGGTCAAGGAAC CTCAGTCACCGTCTCCTCA. IgG Ab # 2 VL:(SEQ ID NO: 14) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVP WTFGGGTKLEIK. (SEQ ID NO: 15) GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGA TCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTGTACATAGTAATG GAAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAG CTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTT CAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGG AGGCTGAGGATCTGGGAGTTTATTTCTGCTTTCAAGGTTCACATGTTCCG TGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA. IgG Ab # 2 CDR:(SEQ ID NO: 16) CDR-H1 - GYSFTSYW. (SEQ ID NO: 17) CDR-H2 - IYPGNSDT. (SEQ ID NO: 18) CDR-H3 - TRSQFYSGSSEDAMDY. (SEQ ID NO: 19) CDR-L1 - QSIVHSNGNTY. (SEQ ID NO: 20) CDR-L2 - KVS. (SEQ ID NO: 21) CDR-L3 - FQGSHVPWT. IgG Ab # 3 VH:(SEQ ID NO: 22) QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWLKQAPGKGLKWMGW INTNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKD YRYWFAYWGQGTLVTVSA. (SEQ ID NO: 23) CAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGAC AGTCAAGATCTCCTGCAAGGCTTCTGGGTATACCTTCACAAACTATGGAA TGAACTGGCTGAAGCAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGG ATAAACACCAACACTGGAGAGCCAACATATGCTGAAGAGTTCAAGGGACG GTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCA ACAACCTCAAAAATGAGGACACGGCTACATATTTCTGTGCAAGAAAGGAC TATAGGTACTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTC TGCA. IgG Ab # 3 VL:(SEQ ID NO: 24) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVP FTFGSGTKLEIK. (SEQ ID NO: 25) GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGA TCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTGTACATAGTAATG GAAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAG CTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTT CAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGG AGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGTTCCA TTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA. IgG Ab # 3 CDR:(SEQ ID NO: 26) CDR-H1 - GYTFTNYG. (SEQ ID NO: 27) CDR-H2 - INTNTGEP. (SEQ ID NO: 28) CDR-H3 - ARKDYRYWFAY. (SEQ ID NO: 29) CDR-L1 - QSIVHSNGNTY. (SEQ ID NO: 30) CDR-L2 - KVS. (SEQ ID NO: 31) CDR-L3 - FQGSHVPFT. - Also tested is whether the monoclonal antibodies produced according to Example 2 can serve as effective antibiotic drugs that could be used in conjunction with conventional antibiotics, as current therapeutic options for treatment of multidrug-resistant P. aeruginosa are very limited. As shown in
FIG. 7 , the mAbs prevented liquid crystal formation of Pf4-polymer solutions suggesting that the mAbs have the same activities as the anti-Pf4 antibodies present in the antiserum of Example 2. - As used herein, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a marker can include multiple markers unless the context clearly dictates otherwise.
- As used herein, the terms “substantially,” “substantial,” and “about” are used to describe and account for small variations. When used in conjunction with an event or circumstance, the terms can refer to instances in which the event or circumstance occurs precisely as well as instances in which the event or circumstance occurs to a close approximation. For example, the terms can refer to less than or equal to ±10%, such as less than or equal to ±5%, less than or equal to ±4%, less than or equal to ±3%, less than or equal to ±2%, less than or equal to ±1%, less than or equal to ±0.5%, less than or equal to ±0.1%, or less than or equal to ±0.05%.
- Additionally, amounts, ratios, and other numerical values are sometimes presented herein in a range format. It is to be understood that such range format is used for convenience and brevity and should be understood flexibly to include numerical values explicitly specified as limits of a range, but also to include all individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly specified. For example, a ratio in the range of about 1 to about 200 should be understood to include the explicitly recited limits of about 1 and about 200, but also to include individual ratios such as about 2, about 3, and about 4, and sub-ranges such as about 10 to about 50, about 20 to about 100, and so forth.
- In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations, which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and/or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scopes of this invention.
Claims (20)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/219,073 US20170021020A1 (en) | 2015-07-23 | 2016-07-25 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
US16/262,548 US10835607B2 (en) | 2015-07-23 | 2019-01-30 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
US17/066,005 US11911472B2 (en) | 2015-07-23 | 2020-10-08 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562196147P | 2015-07-23 | 2015-07-23 | |
US15/219,073 US20170021020A1 (en) | 2015-07-23 | 2016-07-25 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/262,548 Continuation US10835607B2 (en) | 2015-07-23 | 2019-01-30 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170021020A1 true US20170021020A1 (en) | 2017-01-26 |
Family
ID=57836392
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/219,073 Abandoned US20170021020A1 (en) | 2015-07-23 | 2016-07-25 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
US16/262,548 Active US10835607B2 (en) | 2015-07-23 | 2019-01-30 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
US17/066,005 Active 2037-10-06 US11911472B2 (en) | 2015-07-23 | 2020-10-08 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/262,548 Active US10835607B2 (en) | 2015-07-23 | 2019-01-30 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
US17/066,005 Active 2037-10-06 US11911472B2 (en) | 2015-07-23 | 2020-10-08 | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
Country Status (1)
Country | Link |
---|---|
US (3) | US20170021020A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
US10751382B2 (en) | 2016-11-09 | 2020-08-25 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
KR20210062138A (en) * | 2019-11-20 | 2021-05-31 | 대한민국(농림축산식품부 농림축산검역본부장) | Monoclonal Antibody specific for swine influenza virus and Use thereof |
US11970522B2 (en) | 2020-08-28 | 2024-04-30 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170021020A1 (en) | 2015-07-23 | 2017-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
WO2022060905A1 (en) * | 2020-09-15 | 2022-03-24 | The University Of Montana | Compositions and methods targeting filamentous bacteriophage |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573921A (en) * | 1992-09-04 | 1996-11-12 | Dragerwerk Aktiengesellschaft | Immunochemical displacement for determining an analyte |
US20030113742A1 (en) * | 2001-04-20 | 2003-06-19 | University Of Iowa Research Foundation | Methods and compositions for the modulation of biofilm formation |
US20100028378A1 (en) * | 2004-11-15 | 2010-02-04 | Newsouth Innovations Pty. Limited | Toxin-antitoxin system and applications thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101796073B (en) | 2007-02-01 | 2014-08-13 | 特瓦生物制药美国有限公司 | Humanized antibodies against CXCR3 |
EP2220122A2 (en) | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
WO2011111180A1 (en) | 2010-03-10 | 2011-09-15 | 株式会社山武 | Physical quantity sensor and physical quantity measuring method |
US20170021020A1 (en) | 2015-07-23 | 2017-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal antibody and vaccine targeting filamentous bacteriophage |
-
2016
- 2016-07-25 US US15/219,073 patent/US20170021020A1/en not_active Abandoned
-
2019
- 2019-01-30 US US16/262,548 patent/US10835607B2/en active Active
-
2020
- 2020-10-08 US US17/066,005 patent/US11911472B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573921A (en) * | 1992-09-04 | 1996-11-12 | Dragerwerk Aktiengesellschaft | Immunochemical displacement for determining an analyte |
US20030113742A1 (en) * | 2001-04-20 | 2003-06-19 | University Of Iowa Research Foundation | Methods and compositions for the modulation of biofilm formation |
US20100028378A1 (en) * | 2004-11-15 | 2010-02-04 | Newsouth Innovations Pty. Limited | Toxin-antitoxin system and applications thereof |
Non-Patent Citations (1)
Title |
---|
Campbell AM. In: Monoclonal Antibody Technology. Elsevier Science Publishers, The Netherlands, Chapter 1, pages 1-32, 1984 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US11905318B2 (en) | 2015-11-09 | 2024-02-20 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide |
US10751382B2 (en) | 2016-11-09 | 2020-08-25 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US11779629B2 (en) | 2016-11-09 | 2023-10-10 | The University Of British Columbia | Compositions comprising cyclic peptides derived from an A-beta peptide |
WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
KR20210062138A (en) * | 2019-11-20 | 2021-05-31 | 대한민국(농림축산식품부 농림축산검역본부장) | Monoclonal Antibody specific for swine influenza virus and Use thereof |
KR102298278B1 (en) | 2019-11-20 | 2021-09-07 | 대한민국 | Monoclonal Antibody specific for swine influenza virus and Use thereof |
US11970522B2 (en) | 2020-08-28 | 2024-04-30 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide |
Also Published As
Publication number | Publication date |
---|---|
US20200038510A1 (en) | 2020-02-06 |
US11911472B2 (en) | 2024-02-27 |
US10835607B2 (en) | 2020-11-17 |
US20210030875A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11911472B2 (en) | Monoclonal antibody and vaccine targeting filamentous bacteriophage | |
JP6758363B2 (en) | How to treat and prevent S. aureus infection and related conditions | |
TWI719938B (en) | Treatment of polybacterial infections | |
JP5096326B2 (en) | Use of Panton-Valentine Leukocidin to Treat and Prevent Staphylococcal Infection | |
AU2012298125B2 (en) | Antibody and antibody-containing composition | |
EP3061818B1 (en) | Anti-lps o11 antibody | |
JP2013515079A (en) | Methods for treating Staphylococcus infections in patients with low levels of pathogenic Pseudomonas aeruginosa infection | |
WO2021052461A1 (en) | Anti-alpha-hemolysin antibody and use thereof | |
JP7110095B2 (en) | How to prevent or treat nosocomial pneumonia | |
JP2018513168A (en) | Anti-staphylococcus aureus antibody combination preparation | |
EP2432804B1 (en) | Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab | |
RU2377251C2 (en) | Treatment of bacterial infections | |
US10449242B2 (en) | Compositions and methods for the treatment and prevention of Ebp pilus-related diseases | |
CN116854813A (en) | Monoclonal antibody for resisting multi-serotype extreme drug-resistant Acinetobacter baumannii and application thereof | |
WO2021233408A1 (en) | ANTI-α-HEMOLYSIN ANTIBODY AND STABILIZING PREPARATION THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF WASHINGTON;REEL/FRAME:040144/0396 Effective date: 20160914 |
|
AS | Assignment |
Owner name: UNIVERSITY OF WASHINGTON, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARKS, WILLIAM C.;SECOR, PATRICK;REEL/FRAME:045302/0128 Effective date: 20150727 |
|
AS | Assignment |
Owner name: SECOR, PATRICK, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF WASHINGTON;REEL/FRAME:048189/0171 Effective date: 20171205 Owner name: PARKS, WILLIAM C., WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF WASHINGTON;REEL/FRAME:048189/0171 Effective date: 20171205 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BOLLYKY, PAUL L., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY;REEL/FRAME:048671/0209 Effective date: 20190201 |
|
AS | Assignment |
Owner name: BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOLLYKY, PAUL L.;REEL/FRAME:049170/0853 Effective date: 20150724 Owner name: BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOLLYKY, PAUL L.;REEL/FRAME:049170/0853 Effective date: 20150724 |
|
AS | Assignment |
Owner name: INIMMUNE CORPORATION, MONTANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLLYKY, PAUL L.;PARKS, WILLIAM;SECOR, PATRICK;SIGNING DATES FROM 20191119 TO 20191206;REEL/FRAME:051773/0026 |